True dat! Nothing like an FDA stamp to add credibility. Also in a sense de-risks the company because there is a high correlation between breakthrough or RMAT designation with final regulatory approvalIm sure there will be some quotable quotes from Dr Maiti at the ASH conference this year in December during his oral presentation on this groundbreaking study....
Ann: ADVENT-AML Phase 1B clinical trial update, page-25
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |